LEADER 04603nam 22006495 450 001 9910437849203321 005 20200703160841.0 010 $a4-431-54556-5 024 7 $a10.1007/978-4-431-54556-9 035 $a(CKB)3710000000085838 035 $a(EBL)1697797 035 $a(OCoLC)881165975 035 $a(SSID)ssj0001185980 035 $a(PQKBManifestationID)11771290 035 $a(PQKBTitleCode)TC0001185980 035 $a(PQKBWorkID)11229783 035 $a(PQKB)10884999 035 $a(DE-He213)978-4-431-54556-9 035 $a(MiAaPQ)EBC1697797 035 $a(PPN)176126287 035 $a(EXLCZ)993710000000085838 100 $a20140131d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aSendai Virus Vector $eAdvantages and Applications /$fedited by Yoshiyuki Nagai 205 $a1st ed. 2013. 210 1$aTokyo :$cSpringer Japan :$cImprint: Springer,$d2013. 215 $a1 online resource (218 p.) 300 $aDescription based upon print version of record. 311 $a4-431-54555-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $a1. Reverse genetics of Mononegavirales: the rabies virus paradigm Karl-Klaus Conzelmann --   2. Sendai virus biology and engineering leading up to the development of a novel class of expression vector Yoshiyuki Nagai and Atsushi Kato --   3. Concept and technology underlying Sendai virus (SeV) vector development Akihiro Iida and Makoto Inoue --   4. Roadmap for development of a replication-deficient Sendai virus vaccine vector (provisional) Marian Wiegand and Wolfgang Neubert --   5. Development of vaccines using SeV vectors against AIDS and other infectious diseases Sayuri Seki and Tetsuro Matano --   6. BioKnife, a modified Sendai virus, to resect malignant tumors Yoshikazu Yonemitsu, Yasuji Ueda and Mamoru Hasegawa --   7. Induction of human pluripotent stem cells by the Sendai virus vector:Establishment of a highly efficient and foot-print free system Noemi Fusaki and Hiroshi Ban --   8. Gene therapy for peripheral arterial disease using Sendai virus vector: From preclinical Studies to the phase I/IIa clinical trial Yoshikazu Yonemitsu, Takuya Matsumoto and Yoshihiko Maehara. 330 $aSendai virus (SeV) is not just a mouse pathogen but is evolving into a cutting-edge component of biotechnology. SeV reverse genetics originating from a pure academic need to settle long-held questions in the biology and pathogenicity of nonsegmented negative strand RNA viruses (Mononegavirales) is about to bear the impressive fruit of multipurpose cytoplasmic (non-integrating) RNA vectors. This book brings together in one source the SeV biology revealed by conventional approaches and reverse genetics, the methods to construct the first-generation SeV vector and to generate safer versions, and the applications in medical settings that have left or are about to leave the laboratory bench. The applications, which already are diverse and have high medical impact, include use as vaccine vectors against AIDS and respiratory virus infections, creation of BioKnife to resect malignant tumors, induction of ?footprint (transgene) free? pluripotent stem cells, and gene therapy for peripheral arterial disease. These achievements?which are just a few of many examples?were attainable only after rigorously incorporating the rich knowledge of SeV biology that has accumulated during the several decades since the discovery of the virus. Application of SeV vector is certain to expand greatly because of its extremely high performance in transgene expression and its remarkable target cell breadth. 606 $aVirology 606 $aGene therapy 606 $aGene expression 606 $aVirology$3https://scigraph.springernature.com/ontologies/product-market-codes/B22003 606 $aGene Therapy$3https://scigraph.springernature.com/ontologies/product-market-codes/B12020 606 $aGene Expression$3https://scigraph.springernature.com/ontologies/product-market-codes/B12010 615 0$aVirology. 615 0$aGene therapy. 615 0$aGene expression. 615 14$aVirology. 615 24$aGene Therapy. 615 24$aGene Expression. 676 $a611.01816 676 $a616.9 676 $a616.9/101 676 $a616.9101 702 $aNagai$b Yoshiyuki$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910437849203321 996 $aSendai Virus Vector$92522639 997 $aUNINA